Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

J. Weber; M. Mandala; M. Del Vecchio; H.J. Gogas; A.M. Arance; C.L. Cowey; S. Dalle; M. Schenker; V. Chiarion-Sileni; I. Marquez-Rodas; J.-J. Grob; M.O. Butler; M.R. Middleton; M. Maio; V. Atkinson; P. Queirolo; R. Gonzalez; R.R. Kudchadkar; M. Smylie; N. Meyer; L. Mortier; M.B. Atkins; G.V. Long; S. Bhatia; C. Lebbé; P. Rutkowski; K. Yokota; N. Yamazaki; T.M. Kim; V. De Pril; J. Sabater; A. Qureshi; J. Larkin; P.A. Ascierto; Massimo Guidoboni

doi:10.1056/NEJMoa1709030

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

J. Weber, M. Mandala, M. Del Vecchio, H.J. Gogas, A.M. Arance, C.L. Cowey, S. Dalle, M. Schenker, V. Chiarion-Sileni, I. Marquez-Rodas, J.-J. Grob, M.O. Butler, M.R. Middleton, M. Maio, V. Atkinson, P. Queirolo, R. Gonzalez, R.R. Kudchadkar, M. Smylie, N. MeyerL. Mortier, M.B. Atkins, G.V. Long, S. Bhatia, C. Lebbé, P. Rutkowski, K. Yokota, N. Yamazaki, T.M. Kim, V. De Pril, J. Sabater, A. Qureshi, J. Larkin, P.A. Ascierto, Massimo Guidoboni

Research output: Contribution to journal › Article › peer-review

Original language	Italian
Pages (from-to)	1824-1835
Number of pages	12
Journal	New England Journal of Medicine
Volume	377
Issue number	19
DOIs	https://doi.org/10.1056/NEJMoa1709030
Publication status	Published - 2017

Access to Document

10.1056/NEJMoa1709030

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033400433&doi=10.1056%2fNEJMoa1709030&partnerID=40&md5=4a2cc12a116f9146931e427e2403c376

Cite this

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., ... Guidoboni, M. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 377(19), 1824-1835. https://doi.org/10.1056/NEJMoa1709030

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. / Weber, J.; Mandala, M.; Del Vecchio, M.; Gogas, H.J.; Arance, A.M.; Cowey, C.L.; Dalle, S.; Schenker, M.; Chiarion-Sileni, V.; Marquez-Rodas, I.; Grob, J.-J.; Butler, M.O.; Middleton, M.R.; Maio, M.; Atkinson, V.; Queirolo, P.; Gonzalez, R.; Kudchadkar, R.R.; Smylie, M.; Meyer, N.; Mortier, L.; Atkins, M.B.; Long, G.V.; Bhatia, S.; Lebbé, C.; Rutkowski, P.; Yokota, K.; Yamazaki, N.; Kim, T.M.; De Pril, V.; Sabater, J.; Qureshi, A.; Larkin, J.; Ascierto, P.A.; Guidoboni, Massimo.

In: New England Journal of Medicine, Vol. 377, No. 19, 2017, p. 1824-1835.

Research output: Contribution to journal › Article › peer-review

Weber, J, Mandala, M, Del Vecchio, M, Gogas, HJ, Arance, AM, Cowey, CL, Dalle, S, Schenker, M, Chiarion-Sileni, V, Marquez-Rodas, I, Grob, J-J, Butler, MO, Middleton, MR, Maio, M, Atkinson, V, Queirolo, P, Gonzalez, R, Kudchadkar, RR, Smylie, M, Meyer, N, Mortier, L, Atkins, MB, Long, GV, Bhatia, S, Lebbé, C, Rutkowski, P, Yokota, K, Yamazaki, N, Kim, TM, De Pril, V, Sabater, J, Qureshi, A, Larkin, J, Ascierto, PA & Guidoboni, M 2017, 'Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma', New England Journal of Medicine, vol. 377, no. 19, pp. 1824-1835. https://doi.org/10.1056/NEJMoa1709030

Weber, J. ; Mandala, M. ; Del Vecchio, M. ; Gogas, H.J. ; Arance, A.M. ; Cowey, C.L. ; Dalle, S. ; Schenker, M. ; Chiarion-Sileni, V. ; Marquez-Rodas, I. ; Grob, J.-J. ; Butler, M.O. ; Middleton, M.R. ; Maio, M. ; Atkinson, V. ; Queirolo, P. ; Gonzalez, R. ; Kudchadkar, R.R. ; Smylie, M. ; Meyer, N. ; Mortier, L. ; Atkins, M.B. ; Long, G.V. ; Bhatia, S. ; Lebbé, C. ; Rutkowski, P. ; Yokota, K. ; Yamazaki, N. ; Kim, T.M. ; De Pril, V. ; Sabater, J. ; Qureshi, A. ; Larkin, J. ; Ascierto, P.A. ; Guidoboni, Massimo. / Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. In: New England Journal of Medicine. 2017 ; Vol. 377, No. 19. pp. 1824-1835.

@article{b4740b2750cf4dbebfe7709a053e0871,

title = "Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma",

author = "J. Weber and M. Mandala and {Del Vecchio}, M. and H.J. Gogas and A.M. Arance and C.L. Cowey and S. Dalle and M. Schenker and V. Chiarion-Sileni and I. Marquez-Rodas and J.-J. Grob and M.O. Butler and M.R. Middleton and M. Maio and V. Atkinson and P. Queirolo and R. Gonzalez and R.R. Kudchadkar and M. Smylie and N. Meyer and L. Mortier and M.B. Atkins and G.V. Long and S. Bhatia and C. Lebb{\'e} and P. Rutkowski and K. Yokota and N. Yamazaki and T.M. Kim and {De Pril}, V. and J. Sabater and A. Qureshi and J. Larkin and P.A. Ascierto and Massimo Guidoboni",

note = "Cited By :10 Export Date: 12 February 2018",

year = "2017",

doi = "10.1056/NEJMoa1709030",

language = "Italian",

volume = "377",

pages = "1824--1835",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

TY - JOUR

T1 - Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

AU - Weber, J.

AU - Mandala, M.

AU - Del Vecchio, M.

AU - Gogas, H.J.

AU - Arance, A.M.

AU - Cowey, C.L.

AU - Dalle, S.

AU - Schenker, M.

AU - Chiarion-Sileni, V.

AU - Marquez-Rodas, I.

AU - Grob, J.-J.

AU - Butler, M.O.

AU - Middleton, M.R.

AU - Maio, M.

AU - Atkinson, V.

AU - Queirolo, P.

AU - Gonzalez, R.

AU - Kudchadkar, R.R.

AU - Smylie, M.

AU - Meyer, N.

AU - Mortier, L.

AU - Atkins, M.B.

AU - Long, G.V.

AU - Bhatia, S.

AU - Lebbé, C.

AU - Rutkowski, P.

AU - Yokota, K.

AU - Yamazaki, N.

AU - Kim, T.M.

AU - De Pril, V.

AU - Sabater, J.

AU - Qureshi, A.

AU - Larkin, J.

AU - Ascierto, P.A.

AU - Guidoboni, Massimo

N1 - Cited By :10 Export Date: 12 February 2018

PY - 2017

Y1 - 2017

U2 - 10.1056/NEJMoa1709030

DO - 10.1056/NEJMoa1709030

M3 - Articolo

VL - 377

SP - 1824

EP - 1835

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 19

ER -